EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC-ND 4.0

Treatment adherence to oral chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer: Protocol for a hospital pharmacy-based real-world study

Irene Mangues-Bafalluy, Beatriz Bernárdez, José Manuel Martínez-Sesmero, Andres Navarro-Ruiz, Ana Rosa Rubio-Salvador, Maria Teresa Martín-Conde

Farmacia Hospitalaria · 2025

DOI: 10.1016/j.farma.2024.05.016 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Farmacia Hospitalaria, 2025. Verfasst von Irene Mangues-Bafalluy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Grupo de Farmacoepidemiología y Farmacodinamia, Institut de Re…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pharmacy Service, Hospital. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca Farmaceutica Spain SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This article describes a study protocol for evaluating adherence to oral chemotherapy (OCT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in Spain. METHODS: This multicenter, observational, prospective study will be conducted by 6 hospital pharmacists from 6 Spanish hospitals. The study will include men and women aged 18 years or older with a diagnosis of locally advanced or metastatic NSCLC who are being treated or have been prescribed OCT. Once included, the patient will be active and prospectively followed up for 3 months, including 4 study visits to record information on sociodemographic variables, antineoplastic treatment and adherence, pharmaceutical care, clinical variables, and patient-reported outcomes (PRO) (the 3-level version of EQ-5D, the EORTC Core Quality of Life Questionnaire, the Brief Illness Perception Questionnaire, the Treatment Satisfaction with Medicines Questionnaire, and the PRO version of Common Terminology Criteria for Adverse Events). Twelve months after patient inclusion, we will record information on the disease progression status and dispensed prescriptions. The primary outcome is the percentage of treatment adherence that will be calculated based on the pill count as follows: the difference between the number of pills dispensed minus the number of unused pills will be divided by the number of days of treatment multiplied by the number of pills/day prescribed by the oncologist; this quotient will be multiplied by 100 to obtain the percentage of adherence. Based on the that pill count reconciliation, those with a percentage adherence >80% will be primarily categorized as adherent. Secondarily, treatment adherence will be also calculated based on the proportion of days covered and the 4-items Morisky Green Levine Medication Adherence Scale. To analyze the impact of patients' and treatment characteristics on adherence, bivariate analyses will be performed using different adherence cut-off points. To evaluate the impact of adherence on treatment efficacy as evaluated by progression-free survival, we will be using the Kaplan-Meier method and compare it with the log-rank test and univariate Cox regression analysis. CONCLUSIONS: We expect that our study will provide initial information on key aspects of adherence to OCT (i.e., measurement, facilitators, and barriers) and its relationship with patients' and clinically relevant outcomes in the setting of NSCLC, and that this information will help in designing pharmaceutical interventions to improve adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsPharmacy Service, HospitalFemaleHumansMaleMiddle AgedAdministration, OralNeoplasm MetastasisProspective StudiesSpainMulticenter Studies as TopicObservational Studies as Topic

Stichwörter der Autor:innen

AdherenceAdherenciaCáncer de pulmón no microcíticoNon-small cell lung cancerOral chemotherapyPatient-reported outcomesProgression-free survivalQuimioterapia oralResultados comunicados por el pacienteSupervivencia libre de progresión

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Pharmacy Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Grupo de Farmacoepidemiología y Farmacodinamia, Institut de Recerca Biomèdica, IRBLLeida, Lleida, Spain. Electronic address: Imangue…
  • Departamento de Medicina, Universidad de Santiago de Compostela, Santiago, Spain; Unidad de Farmacia Oncológica, Servicio de Farmacia, Hospital Clínico Universitario de Santiago de Compostela, Santiago, Spain; Grupo de…
  • Hospital Clínico Lozano Blesa, Zaragoza, Spain.
  • Pharmacy Department, Hospital General Universitario de Elche, Elche, Spain.
  • Pharmacy Department, Hospital Universitario de Toledo, Toledo, Spain.
  • Pharmacy Department, Hospital Clínic de Barcelona, Barcelona, Spain.

Förderung

  • AstraZeneca Farmaceutica Spain SA

Zitieren

APA

Mangues-Bafalluy, I., Bernárdez, B., Martínez-Sesmero, J. M., Navarro-Ruiz, A., Rubio-Salvador, A. R., & Martín-Conde, M. T. (2025). Treatment adherence to oral chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer: Protocol for a hospital pharmacy-based real-world study. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2024.05.016

Vancouver

Mangues-Bafalluy I, Bernárdez B, Martínez-Sesmero JM, Navarro-Ruiz A, Rubio-Salvador AR, Martín-Conde MT. Treatment adherence to oral chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer: Protocol for a hospital pharmacy-based real-world study. Farmacia Hospitalaria. 2025. doi:10.1016/j.farma.2024.05.016

BibTeX
@article{ManguesBafalluy2025,
  author = {Mangues-Bafalluy, Irene and Bernárdez, Beatriz and Martínez-Sesmero, José Manuel and Navarro-Ruiz, Andres and Rubio-Salvador, Ana Rosa and Martín-Conde, Maria Teresa},
  title = {Treatment adherence to oral chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer: Protocol for a hospital pharmacy-based real-world study},
  journal = {Farmacia Hospitalaria},
  year = {2025},
  doi = {10.1016/j.farma.2024.05.016}
}
Kostenlos starten →